Research On Financial Risks Of Overseas Mergers And Acquisitions Of Pharmaceutical Enterprises

With the integration of the world economy,gradually become a trend of transnational m&a,China also actively implement the strategy of "going out",for the enterprise,a shortcut to overseas mergers and acquisitions is undoubtedly to international,for the purpose of more effective overseas mergers and acquisitions,enterprises must pay more attention to the risk of overseas mergers and acquisitions,especially may cause the failure of mergers and acquisitions of financial risk.For pharmaceutical enterprises,overseas mergers and acquisitions can rapidly enhance their comprehensive strength and obtain core patents,r&d innovation ability,enterprise management experience and marketing channels of foreign pharmaceutical enterprises.Looking at the international market,overseas mergers and acquisitions boom is still in the ascendant.European and American pharmaceutical companies started early in the implementation of overseas mergers and acquisitions and have rich and strong experience and strength in overseas mergers and acquisitions.Therefore,if Chinese pharmaceutical enterprises rashly and blindly conduct overseas mergers and acquisitions,the effect may not be ideal.In this background,this article first to overseas mergers and acquisitions and pharmaceutical enterprise overseas m&a financial risk related theory to comb,from the biological medicine companies at home and abroad with the current situation of overseas m&a,fosun medicine road of overseas mergers and acquisitions as the research object,from fosun medicine m&a facing the financial risk of the common and unique pharmaceutical enterprise m&a financial risk are analyzed,and on this basis to fosun medicine and hengrui pharmaceutical and comparing the relevant data of the entire pharmaceutical industry evaluation,on the basis of the overseas mergers and acquisitions of financial risk control measures to make a summary of this paper.In view of the characteristics of the pharmaceutical industry,this article selects the representative of the pharmaceutical industry enterprises fosun medicine,through case analysis and comparative analysis,from the perspective of industry particularity and typicality enrich and expand the pharmaceutical enterprise overseas m&a financial risk of the case study,on the basis of risk identification,risk analysis,risk evaluation,risk control of each phase of the financial risk analysis summarized,with hope in our pharmaceutical enterprises inoverseas mergers and acquisitions on the financial risk control of help.